Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission for patients who are NOT eligible for hematopoietic cell transplantation (HCT)

This algorithm should be used in conjunction with related UpToDate content regarding transplant eligibility, detection of MRD, maintenance therapy, and related material.

Ph+ ALL: Philadelphia chromosome positive acute lymphoblastic leukemia; CR: hematologic complete remission; MRD: measurable residual disease based on quantitative reverse transcriptase polymerase chain reaction for BCR-ABL1; HCT: hematopoietic cell transplantation; TKI: BCR-ABL1 tyrosine kinase inhibitor.
* MRD detectable in bone marrow: <MR4.5 (BCR-ABL1 >10^–4.5).
¶ TKI should be held during blinatumomab treatment and resumed for maintenance therapy.

Graphic 130442 Version 2.0

خرید پکیج

Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission for patients who are NOT eligible for hematopoietic cell transplantation (HCT)